옵션 체인은 다양한 행사가격과 만기일에 대한 AgEagle Aerial Sys의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 AgEagle Aerial Sys에 대한 시장 심리를 평가합니다..

AgEagle Aerial Sys (AMEX:UAVS) 주식, 옵션 체인

AgEagle Aerial Sys

AgEagle Aerial Systems Inc is actively engaged in designing and delivering drones, sensors and software that solve important problems for its customers. It designs, produces, distributes, and supports technologically advanced small unmanned aerial systems (UAVs) that it offers for sale commercially to the precision agriculture industry. Its segments include Drones, Sensors and Software-as-a-Service (SaaS). The company's majority revenue is derived primarily through sensors.

Stocks.Watch_.Shutterstock

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

APOG

LFCR

MMLP

UAVS

금요일 오전 (현지 시간 기준) 미국 주가 지수 선물이 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 아포지 엔터프라이즈(NASDAQ:APOG)가 분기 이익을 주당 1.23달러, 매출 3억 3,529만 달러로 예상하고 있다. 아포지의 주식은 애프터 마켓에서 0.1% 상승하여 68.50달러에 거래되었다.

금요일 주목해야 할 주식: 아포지 엔터프라이즈, 스마트 샌드 그리고 3종목

AgEagle Aerial Systems, Inc. Common Stock

AgEagle Aerial Systems Inc

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is unchanged from the same period last year.

Earnings Beats

AVXL

Anavex Life Sciences Q2 EPS $(0.13) Beats $(0.15) Estimate

Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 42.31 percent decrease over losses of $(0.26) per share from the same period last year.

ACHV

Achieve Life Sciences Q1 EPS $(0.37), Inline

Alzamend Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in <a target="_blank" href="https://www.benzinga.com/exclusives" rel="noreferrer noopener">healthy human subjects</a>.
This study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43809487/exclusive-alzamend-neuro-says-tesla-dynamic-completes-head-coil-to-measure-brain-structure-lithium-levels" rel="noreferrer noopener">component of the clinical trial</a>.
In collaboration with Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore AL001 and its potential to deliver lithium more effectively in the brain than <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43937141/exclusive-alzamend-neuro-to-start-first-phase-2-study-for-lead-candidate-in-2025" rel="noreferrer noopener">marketed lithium salts</a>.
The study in healthy human subjects will serve as a baseline and assist Alzamend to determine the best path forward in Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder patients by demonstrating AL001's targeted effectiveness and reduced systemic side effects.
Topline data is expected by the end of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45249094/exclusive-alzamend-neuro-partners-with-qmenta-to-advance-ai-powered-imaging-for-is-phase-2-trial-of-lead-program" rel="noreferrer noopener">EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program</a>
Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.
In March, Alzamend Neuro&nbsp;announced its plans to initiate a phase 2 clinical study of AL001 for patients with post-traumatic stress disorder in the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44243481/exclusive-alzamend-neuro-to-launch-phase-2-study-for-lead-drug-for-ptsd-patients-in-late-2025-to-assess-lithium-delivery-benefits" rel="noreferrer noopener">fourth quarter of 2025</a>.
In November 2024, Alzamend Neuro finished analyzing a nonclinical study's final full data set comparing brain and plasma lithium exposures between AL001 and lithium carbonate in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42059707/exclusive-alzamend-neuro-reveals-full-data-from-nonclinical-study-of-its-lead-alzheimers-drug-potential" rel="noreferrer noopener">Alzheimer's transgenic mice</a>.
The study involved administering AL001 to 5XFAD mice, a recognized model for Alzheimer's research, to compare its effects against lithium carbonate, an FDA-approved and marketed API.
Mice received high or low doses, scaled to humans, of AL001 and lithium carbonate over 14 days to observe pharmacokinetic steady-state drug conditions.
Last week, the company's board of directors approved a one-for-nine reverse stock split of its common stock to maintain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45282840/alzamend-neuro-announces-reverse-stock-split" rel="noreferrer noopener">Nasdaq Capital Market</a>.
Price Action: At the last check on Tuesday, ALZN stock was up 6.57% to $5.49 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45358050/nano-cap-neurosense-therapeutics-gets-14-price-forecast-as-primec-nears-key-als-milestones" target="_blank" rel="noreferrer noopener">Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

ALZN

EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

EXLCUSIVE: Alzamend Neuro Tells Benzinga 'Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects'

EXLCUSIVE: Alzamend Neuro Tells Benzinga 'Topline data expected by year end'

EXLCUSIVE: Alzamend Neuro Tells Benzinga Co. Initiates First Phase II Clinical Trial Of AL001 Lithium Brain Study Taking Place At Massachusetts General Hospital

Canaccord Genuity analyst Joseph Vafi maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Buy and lowers the price target from $105 to $75.

Price Target

Analyst Ratings

BILL

Canaccord Genuity Maintains Buy on BILL Holdings, Lowers Price Target to $75

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Buy and lowers the price target from $22 to $20.

LXEO

Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $20

Needham analyst Joshua Reilly reiterates ZoomInfo Technologies Inc. - Common Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTM#NASDAQ">GTM</a>) with a Buy and maintains $15 price target.

Reiteration

Needham Reiterates Buy on ZoomInfo Technologies Inc. - Common Stock, Maintains $15 Price Target

WIIM

CYBR

CyberArk Software shares are trading lower. The company reported Q1 financial results.

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">CPI Card Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, CPI Card reported worse-than-expected first-quarter earnings. &#8220;We are pleased with our first quarter sales performance, led by strong growth from our debit and credit card portfolio,&#8221; said John Lowe, President and Chief Executive Officer. &#8220;Our outlook remains intact, and we plan to continue to execute our strategies to gain share and diversify our business, as evidenced by our acquisition of Arroweye Solutions.&#8221; The company's stock fell around 22% over the past five days and has a 52-week low of $18.46.</li>
<li>RSI Value: 29.4</li>
<li>PMTS Price Action: Shares of CPI Card fell 4.8% to close at $20.48 on Monday.</li>
<li>Edge Stock Ratings: 26.27 Momentum score with Value at 43.86. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/PMTS"><img loading="lazy" decoding="async" width="470" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134.png" alt="" class="wp-image-913102" style="width:372px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134.png 470w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134-300x110.png 300w" sizes="(max-width: 470px) 100vw, 470px" /></a></figure>
<h3 class="wp-block-heading">Astrotech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTC#NASDAQ">ASTC</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On Feb. 14, Astrotech reported its financial results for the second quarter of fiscal year 2025, which ended Dec. 31, 2024. Thomas B. Pickens, III, Astrotech&#8217;s Chairman, Chief Executive Officer and Chief Technology Officer, said &#8220;We are now prioritizing and accelerating our attention to selling and marketing our line of portable, rugged and inexpensive mass spectrometry instruments. We believe 1st Detect&#8217;s explosive trace detection products are now proven with four years of use in cargo warehouses having run thousands of samples at airports in 14 countries.&#8221; The company's stock fell around 16% over the past six months and <a href="https://www.benzinga.com/quote/ASTC">has a 52-week low</a> of $5.72.</li>
<li>RSI Value: 26.1</li>
<li>ASTC Price Action: Shares of Astrotech gained 2.3% to close at $5.90 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">ASTC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="922" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135.png" alt="" class="wp-image-913105" style="width:523px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135-768x701.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">reAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>)</h3>
<ul class="wp-block-list">
<li>On April 28, reAlpha Tech announced the appointment of Cristol Rippe as Chief Marketing Officer. &#8220;Cristol&#8217;s arrival marks an exciting new chapter for the reAlpha executive team,&#8221; said Mike Logozzo, President and Chief Operating Officer of reAlpha. The company's stock fell around 16% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/AIRE">low of $0.51.</a></li>
<li>RSI Value: 29.2</li>
<li>AIRE Price Action: Shares of reAlpha Tech fell 0.1% to close at $0.58 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">AIRE shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="868" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136.png" alt="" class="wp-image-913108" style="width:616px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136.png 868w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136-768x726.png 768w" sizes="(max-width: 868px) 100vw, 868px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

AIRE

ASTC

PMTS

Top 3 Tech Stocks Which Could Rescue Your Portfolio This Quarter

Honda Motor shares are trading lower after the company reported a year-over-year decrease in FY25 GAAP EPS results.

ONON

On Holding shares are trading higher after the company reported better-than-expected Q1 financial results.

Immatics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMTX#NASDAQ">IMTX</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 6.06 percent. This is a 713.95 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $19.54 million which beat the analyst consensus estimate of $15.42 million by 26.73 percent. This is a 40.56 percent decrease over sales of $32.87 million the same period last year.

Earnings Misses

IMTX

Immatics Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $19.54M Beat $15.42M Estimate

WestPark Capital analyst Casey Ryan reiterates Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $2.22 price target.

INVZ

WestPark Capital Reiterates Buy on Innoviz Technologies, Maintains $2.22 Price Target

UnitedHealth Group shares are trading lower after the company announced it suspended its FY25 guidance. The company announced the appointment of Stephen Hemsley as CEO.

<ul>
<li>WonderFi will join Robinhood Crypto and continue to deliver crypto products to Canadian customers</li>
<li>WonderFi shareholders to receive all-cash consideration of C$0.36 per Common Share</li>
<li>Purchase price represents an attractive premium of approximately 41% to the closing price, and 71% to the 30-day VWAP, as of May 12</li>
</ul>

HOOD

Robinhood To Acquire WonderFi, A Canadian Crypto Platform, For C$250M In All-Cash Deal At C$0.36 Per Share

New BD FACSDiscover&#x2122; A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma
FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more researchers across a wider range of applications to uncover deeper insights and dynamics from cells once invisible in flow cytometry experiments – with increased ease and throughput.

BD Launches FACSDiscover A8 Cell Analyzer, Featuring Spectral And Real-Time Cell Imaging Technologies For Scientists In Academia And Biopharma

Needham analyst Charles Shi reiterates Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Buy and maintains $325 price target.

CDNS

Needham Reiterates Buy on Cadence Design Systems, Maintains $325 Price Target

COIN

Coinbase Global shares are trading higher it was announced that the company will join the S&P 500, effective before the opening of trading on Monday, May 19.

Press Releases

AgEagle Showcases eBee VISION Drone at 173rd Airborne Brigade Innovation Symposium

AgEagle Aerial Systems Announces Appointment of Alison Burgett as Chief Financial Officer

Small Cap

Opinion

Multi-Billion Dollar Global Drone Industry Showing Resilience and Adaptability as Further Expansion & Growth Expected

AgEagle Aerial Systems Announces Evolution new release of eBee VISION Application Software Featuring Manual Drone Navigation Without Global Navigation Satellite System (GNSS) Signals

Global Drone Usage and Adoption Continues to Skyrocket While Largely Benefiting the Agriculture Industry

AgEagle Aerial Systems Releases Latest eBee VISION Application Software Featuring Updated Autonomous Drone Navigation Without Global Navigation Satellite System (GNSS) Signals

AgEagle Aerial Systems Receives Non-Compliance Notice from NYSE American and Makes NYSE American Section 610(b) Public Announcement

AgEagle Aerial Systems Showcases eBee VISION and eBee TAC Capability to European Customers

Drone-Mounted Lidar Systems for Bathymetric Surveys Market Expected to Reach $890 Million By 2032

AgEagle Aerial Systems Secures Additional Sale of eBee VISION Drones to the British Antarctic Survey

Comments

AgEagle Aerial Sys

AgEagle Aerial Sys (UAVS) 옵션

AgEagle Aerial Sys (AMEX:UAVS) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌